Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective - Concepedia

Concepedia

Publication | Open Access

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

DOI Full Paper Access

16

Citations

18

References

2011

Year

A Alvarado Duran, Nishan Sengupta, Fiona Forster, Louis M. Kwong, Michael Lees

Journal of Medical Economics

Abstract

In this model, rivaroxaban reduced total treatment payer costs vs enoxaparin for the prevention of VTE in THR or TKR patients.

References

	Year	Citations

Page 1